Key Takeaways
- RIVANNA® has received FDA clearance for the Accuro® XV Diagnostic Ultrasound System for musculoskeletal imaging.
- The Accuro XV features AI-enabled capabilities like BoneEnhance® and CADe/x for enhanced bone visualization and fracture identification.
- This clearance marks a significant milestone for RIVANNA, positioning them to redefine the standard of care for extremity injury triage.
RIVANNA® Revolutionizes Musculoskeletal Imaging with AI-Enabled Ultrasound System
RIVANNA®, a pioneer in AI-enabled clinical decision-support solutions, has recently received FDA clearance for their groundbreaking Accuro® XV Diagnostic Ultrasound System. This clearance signifies a major regulatory milestone, allowing qualified healthcare professionals to use the Accuro XV for musculoskeletal imaging in hospital and medical clinic settings.
AI-Enabled Capabilities Enhance Diagnostic Potential
One of the key features of the Accuro XV is its AI-enabled capabilities, including BoneEnhance® for enhanced bone visualization and CADe/x, the first computer-aided detection algorithm for automated fracture identification derived from volumetric ultrasound imaging. These capabilities are currently undergoing validation through a multi-site clinical study spanning eight academic medical centers nationwide.
Democratizing Access to High-Quality Imaging
With the combination of automated acquisition technology and AI-enabled fracture detection, the Accuro XV has the potential to democratize access to high-quality musculoskeletal imaging. This innovative system could also help reduce the burden on imaging resources in high-volume emergency settings, providing faster and more accurate diagnoses for patients.
Feasibility Study Validates System's Effectiveness
A recent feasibility study conducted at UVA Health and UT Southwestern Medical Center has demonstrated the effectiveness of the Accuro XV system. Non-physician operators were able to acquire diagnostic-quality extremity images after just one hour of hands-on training, with image quality comparable to that achieved by board-certified emergency physicians. This study further highlights the potential impact of the Accuro XV in improving patient care.
Overall, the FDA clearance of the Accuro XV represents a significant step forward in musculoskeletal imaging technology. With its AI-enabled capabilities and user-friendly design, this system has the potential to revolutionize the way extremity injuries are triaged and diagnosed, setting a new standard of care in the field of musculoskeletal ultrasound.